BRCA1 and ovarian carcinoma: Thus, measuring the levels of BRCA1 and BRCA2 mRNAs in ovarian cancers using either the NanoString nCounter system or ddPCR may help predict which patients will benefit the most from platinum-based chemotherapy and PARPi when DNA tests are negative or inconclusive.